内镜下自体黏膜移植治疗慢性不愈合管腔缺损
本研究在2个三级中心对8例慢性不愈合消化道缺损患者行内镜下自体黏膜移植(EAMT),技术成功率100%,临床成功率87.5%,无操作相关不良事件,提示EAMT对常规治疗失败的选择性患者可行且安全。
要点
- EAMT技术成功率100%,临床成功率87.5%,无操作相关早期或晚期不良事件。
- 1例大缺损(80 mm)需再次操作完成受区完全闭合,所有移植物复查内镜均存活。
- 1例合并炎症性肠病患者6个月时症状复发。
核心结论
- EAMT对常规治疗失败的慢性消化道管腔缺损经选择的患者技术上可行且安全,为传统闭合技术提供了新的修复思路。
研究设计与样本
- 在2个三级中心开展的研究,纳入接受EAMT的成年患者,采用标准化操作方案并记录结局。
主要发现
- 共8例患者接受EAMT,平均年龄64.6±10.0岁,6例(75%)为男性。
- 适应证包括不愈合胃空肠吻合口边缘溃疡、空肠储袋瘘、胃穿孔术后胃瘘、Roux-en-Y旁路术后胃胃瘘、术后十二指肠球部瘘、缺血性胃十二指肠溃疡及术后支气管食管瘘。
- 技术成功率100%(8/8),除1例80 mm大缺损需额外操作外其余同次完成受区完全闭合。
- 重复内镜显示所有移植物存活,中位随访12.7周,临床成功率87.5%(7/8)。
- 1例(12.5%)合并炎症性肠病患者6个月时症状复发,未记录操作相关早期或晚期不良事件。
临床怎么用
- 对常规闭合技术失败的慢性不愈合消化道管腔缺损,EAMT可作为经选择患者的可选修复策略。
- 大缺损可能需要额外操作以实现受区完全闭合,术后需内镜随访评估移植物存活。
局限性
- 样本量小(8例),随访时间短,结论需进一步研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Chronic nonhealing GI defects remain difficult to manage. Existing techniques for endoscopic closure rely heavily on mechanical tissue approximation and may fail when the surrounding tissue is ischemic, indurated, fibrotic, or chronically inflamed. Endoscopic autologous mucosal transplantation (EAMT) is a novel approach in which viable mucosal tissue is harvested from the same patient and transplanted onto the chronic defect to promote tissue regeneration. METHODS: We conducted a study at 2 tertiary care centers, involving adult patients who underwent EAMT. A standardized procedural protocol was used for consistent reproducibility and reporting, and outcomes were recorded. RESULTS: A total of 8 patients underwent EAMT. The mean age was 64.6 ± 10.0 years, and 6 patients (75%) were male. All treated defects were chronic. Indications included a nonhealing gastrojejunal marginal ulcer (n = 1), jejunal pouch fistula (n = 1), gastric fistula after surgical repair of a gastric perforation (n = 1), gastrogastric fistula after Roux-en-Y bypass (n = 1), duodenal bulb fistula after surgical repair (n = 1), ischemic gastroduodenal ulcer (n = 1), and postoperative bronchoesophageal fistulae (n = 2). The median defect size was 15.0 mm (range, 80-85). The median procedure time was 73 minutes (range, 135-145). The technical success rate was achieved in all 8 cases (100%). Same-session complete closure of the recipient site was achieved in all patients except 1 with a large defect (80 mm), who required an additional procedure. All grafts were viable on repeat endoscopy. The median follow-up duration was 12.7 weeks (range, 26-28). The clinical success rate was observed in 7 patients (87.5%). One patient (12.5%), with underlying inflammatory bowel disease, experienced symptom recurrence at 6 months. There were no procedure-related early or late adverse events recorded. CONCLUSIONS: EAMT appears to be technically feasible and safe for the management of chronic GI luminal defects in carefully selected patients who have failed conventional therapy. EMAT offers a novel restorative approach that differs conceptually from conventional closure techniques and may expand therapeutic options for patients with complex nonhealing defects. Further studies are needed.
引用
- Kadkhodayan K, Shariq Mohammed AS, Hayat M, et al. Endoscopic autologous mucosal transplantation for management of chronic nonhealing luminal defects (with video). Gastrointest Endosc. 2026. PMID: 42349758. doi:10.1016/j.gie.2026.06.039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。